Scarica l'app Stockscreener
1.09
2.83%
0.03
Dopo l'orario di chiusura:
1.09
Citius Oncology Inc Borsa (CTOR) Ultime notizie
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
CTOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Outlook: Can Citius Oncology Inc keep up with sector leadersJuly 2025 Highlights & High Accuracy Buy Signal Tips - baoquankhu1.vn
Aug Selloffs: What are Merus NVs earnings expectationsMarket Weekly Review & Smart Swing Trading Alerts - baoquankhu1.vn
Aug Drivers: Is TCRT stock showing strong momentumMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Is Citius Oncology Inc. stock a contrarian buyTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug PreEarnings: Can Citius Oncology Inc lead its sector in growth2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Armistice Capital reports 8.08M Citius Oncology (NASDAQ: CTOR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
CTOR PE Ratio & Valuation, Is CTOR Overvalued - Intellectia AI
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat
Earnings Breakdown: Citius Oncology Q1 - Benzinga
CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Press Release: Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM) - 富途牛牛
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Sahm
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius inks EU distribution agreement for CTCL treatment - The Pharma Letter
Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir - Bitget
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
CITIUS ONCOLOGY Q1 2026 Earnings Preview: Recent $CTOR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday - MarketBeat
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January - MarketBeat
Interleukin-2 (IL-2) Market to Grow Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eisai, Citius Oncology, Corvus Pharmaceuticals, ILTOO Pharma - Barchart.com
CEO Moves: Why is Citius Oncology Inc stock going down2025 Trading Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Decliners Report: Is Citius Oncology Inc undervalued by DCF analysisJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com
Dow Update: Why is Citius Oncology Inc stock going downWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2% - MarketBeat
Profit Review: Is Citius Oncology Inc likely to announce a buybackJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st
Can Citius Oncology Inc. stock beat market expectations this quarterJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
Does Citius Oncology Inc. stock trade at a discount to peersPrice Action & Daily Chart Pattern Signals - Улправда
How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - Улправда
Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда
Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Oncology raises $18M through direct offering - MSN
News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - marketscreener.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - PR Newswire
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):